Can PepFold design peptides for rs7412?

Yes. PepFold accepts rs7412 as input, annotates it via ClinVar, maps it to the APOE protein via UniProt, generates peptide candidates targeting affected functional domains, predicts their 3D structures with ESMFold, and produces a scored report with Fmoc-SPPS synthesis protocols.

SNP Database

rs7412 — APOE APOE2 (Arg158Cys)

Q: What gene is rs7412 in?

rs7412 is a variant in the APOE (Apolipoprotein E) gene located on chromosome 19q13.32. Lipid transport, cholesterol metabolism, neuronal repair, and amyloid-beta clearance in the brain. APOE is the major genetic risk modulator for late-onset Alzheimer's disease.

Q: What is the clinical significance of rs7412?

rs7412 is classified as "Protective / Risk factor" in ClinVar. APOE2 has reduced binding affinity for LDL receptors (~2% of normal), leading to impaired clearance of intermediate-density lipoproteins. This paradoxically provides neuroprotection while creating cardiovascular risk in homozygotes.

Protective / Risk factor · ~8% global allele frequency

rs7412 defines the APOE2 allele through an arginine-to-cysteine substitution at position 158. APOE2 is protective against Alzheimer's disease but associated with type III hyperlipoproteinemia when homozygous.

Molecular Mechanism

APOE2 has reduced binding affinity for LDL receptors (~2% of normal), leading to impaired clearance of intermediate-density lipoproteins. This paradoxically provides neuroprotection while creating cardiovascular risk in homozygotes.

Peptide Therapeutic Relevance

Peptides targeting APOE-receptor binding interfaces could modulate lipid clearance. PepFold generates candidates exploring the Arg158Cys region and receptor interaction domains.

Gene: APOE (Apolipoprotein E)

Lipid transport, cholesterol metabolism, neuronal repair, and amyloid-beta clearance in the brain. APOE is the major genetic risk modulator for late-onset Alzheimer's disease.

Chromosome 19q13.32

Full APOE gene profile →

Condition: Cardiovascular Disease (Genetic Risk)

Genetic variants in APOE, AGT, AGTR1, and lipid metabolism genes contribute to cardiovascular risk. Pharmacogenomics guides anticoagulant, antiplatelet, and antihypertensive therapy selection.

Prevalence: Leading cause of death globally: 17.9 million deaths/year (WHO 2023)

Full Cardiovascular Disease (Genetic Risk) profile →

Related Variants

rs429358APOE — APOE4 (Cys112Arg)

Analyze rs7412 with PepFold

Submit rs7412 and get ranked peptide candidates with 3D structures and synthesis protocols in under 2 minutes.

Try Analysis View Pricing